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A population pharmacokinetic model based on data from three phase I studies was to be developed including a covariate analysis to
describe the concentration–time profiles of matuzumab, a novel humanised monoclonal antibody. Matuzumab was administered as
multiple 1h i.v. infusions with 11 different dosing regimens ranging from 400 to 2000mg, q1w–q3w. For analysis, 90 patients with
1256 serum concentration–time data were simultaneously fitted using the software NONMEMt. Data were best described using a
two-compartment model with the parameters central (V1) and peripheral distribution volume (V2), intercompartmental (Q) and linear
(CLL) clearance and an additional nonlinear elimination pathway (Km, Vmax). Structural parameters were in agreement with
immunoglobulin characteristics. In total, interindividual variability on Vmax, CLL, V1 and V2 and interoccasion variability on CLL was
22–62% CV. A covariate analysis identified weight having an influence on V1 (þ0.44% per kg) and CLL (þ0.87% per kg). All
parameters were estimated with good precision (RSEo39%). A robust population pharmacokinetic model for matuzumab was
developed, including a nonlinear pharmacokinetic process. In addition, relevant and plausible covariates were identified and
incorporated into the model. When correlated to efficacy, this model could serve as a tool to guide dose selection for this ‘targeted’
cancer therapy.
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Recent discoveries in biomolecular processes in tumour growth led
to the evolution of new targeted therapies in cancer treatment
(Ross et al, 2003). Monoclonal antibodies as one of these new
potential therapeutic agents benefit from their ability to bind to
specific structural targets leading to good clinical efficacy and a
general lower incidence of adverse events than small molecule
therapeutics (Stern and Herrmann, 2005).
Matuzumab is a humanised recombinant monoclonal antibody
(mAb) of the immunoglobulin subclass IgG1 (k-chain) targeting
the epidermal growth factor receptor (EGFR, HER1 and c-ErbB-1)
(Kollmannsberger et al, 2006). This physiological transmembrane
receptor with protein tyrosine kinase activity is activated by
natural ligands such as epidermal growth factor and transforming
growth factor-a (Watanabe et al, 1994; Wells, 1999; Harari, 2004).
The EGFR is constitutively expressed in many healthy epithelial
tissues, including skin and hair follicle. It is overexpressed or
upregulated in a variety of tumour entities (e.g. colon, mamma and
bronchial carcinoma) and is often associated with a high
metastatic rate, poor prognosis and advanced disease progression
(Dassonville et al, 1993; Rusch et al, 1993; Salomon et al, 1995).
Epidermal growth factor receptor can be used as a target for
therapies based on blockade of receptor–ligand interactions and
inhibition of downstream signalling pathways such as cell
proliferation, angiogenesis and invasion as well as increase of
apoptosis (Ritter and Arteaga, 2003; Li et al, 2005). Epidermal
growth factor receptor and other members of this receptor
family have already been successful targets for cancer therapy
(Wells, 1999).
The history of targeting the EGFR with matuzumab started with
the murine mAb 425 generated by immunisation of mice (Murthy
et al, 1987). From a subclone, the antibody EMD55900 was
produced causing immune reactions in patients by developing
human anti-mouse antibodies.
The first approved mAb targeting EGFR as a single agent or in
combination with irinotecan in patients with EGFR-expressing,
metastatic and irinotecan-refractory colorectal carcinoma is the
chimeric mAb cetuximab (Harding and Burtness, 2005), which has
shown favourable efficacy (Cunningham et al, 2004).
The most common adverse reaction was reported to be skin
toxicity, including acneform rash. To overcome the disadvantages
of the murine or chimeric mAbs and to not or only marginally
induce anti-antibodies and cause an immune response, the
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shumanisation of the murine mAb 425 was performed, according to
the method of G. Winter and as described by Kettleborough et al
(1991). The humanised mAb matuzumab has already shown
promising activity in several phase I and phase II studies in the
treatment of different tumour entities (Vanhoefer et al, 2004).
The overall aim of this population analysis was to develop a PK
model comprehensively characterising the pharmacokinetics of
matuzumab. An accurate description of the typical PK profile and
of different variability types over a broad range of dosing regimens
was to be provided. In addition, patient-specific characteristics
should be attempted to be identified to explain the variability of
the PK parameters and to further guide dosage regimen decisions
for following trials.
MATERIALS AND METHODS
Patient population, treatment and data collection
This study included 90 patients (53 males and 37 females) from
three phase I, open labelled, nonrandomised, uncontrolled, multi-
centre studies. The patients had different types of advanced
carcinoma. The main criteria for inclusion encompassed histolo-
gically proven carcinoma in advanced, nonresectable and/or
metastatic state, Karnofsky performance status X60%, life
expectancy 412 weeks (1 study 48 weeks), no prior chemo- or
radiotherapy within the last 3 or 4 weeks prior to study start,
adequate renal, haematological and hepatic function, age X18
years. Patients were excluded if they had known brain metastases,
were pregnant or had other relevant medical criteria. All patients
gave written informed consent prior to inclusion into the study.
The clinical studies were carried out after approval from ethics
committee.
Patients received matuzumab as multiple 1h i.v. infusions in a
constant dosing regimen. A wide range of dosing regimens was
covered by different groups of patients. In study 1, matuzumab
was administered starting with 400mg weekly, followed by 800mg
biweekly and up to 800mg every week in combination with a fixed
dose of gemcitabine (1000mgm
 2). Study 2 included the
administration of 400, 800, 1200 and 1600mg with a 3-week
interval and, additionally, 1200mg biweekly and weekly adminis-
tration. In study 3, matuzumab was given 400, 800, 1200 or
1600mg once weekly. Some patients were treated over a longer
time period of approximately 1 year.
Serum samples were taken pre- and post-infusions. Frequent
serum samples were taken after the first infusion and after the
infusion given 3 weeks later. Before and after several other
infusions peak and trough concentrations were analysed. Details of
dose regimens and sampling schedules are presented in Table 1.
Frozen samples were shipped to the Institute of Drug Metabolism
and Pharmacokinetics, Merck KGaA, Grafing, Germany, for
bioanalysis. Serum levels were evaluated using a validated
sandwich enzyme-linked immunosorbent assay method, as de-
scribed previously (Vanhoefer et al, 2004). Precision and accuracy
met the international recommendations for bioanalytical immuno-
assays (DeSilva et al, 2003).
Population pharmacokinetic analysis
The population PK analysis was performed with serum mAb
concentration data and associated data such as demographics from
all three studies. The population PK model building process was
performed using the nonlinear mixed-effects modelling approach
implemented in the software NONMEMt, version V, level 1.1.
Model development was performed stepwise. First a structural
model was developed including an investigation of different
compartment models. During model refinement, linear and
nonlinear processes and elimination pathways were included.
During the development of the base model and at later stages,
interindividual, residual and interoccasion variabilities were
investigated. As part of the statistical submodel, the interindividual
variability (IIV) was modelled with an exponential random effects
term:
Pki ¼ yk   eZki
where Pki represents the parameter value k from the individual i
and yk describes the population value of the parameter k. Zki
denotes the ln-difference between Pki and yk. The interoccasion
variability (IOV), that is the variability within one individual
between study occasions, was also examined with an exponential
random effects term:
Pkiq ¼ yk   eZkiþkkiq
where Pkiq is the individual parameter value k from the individual i
at the occasion q that differs from the typical individual value by
an additional random effect kkiq. An occasion was characterised as
the time period from the start of an infusion and until the start of
the next administration. Zki and kkiq were assumed to be
symmetrically distributed with a zero mean and a variance of o
2
and p
2, respectively.
Residual variability represents the discrepancy between the
observed and the model-predicted concentrations after incorpora-
tion of IIV and IOV. It was modelled using additive, proportional
or combined error models.
All models were parameterised in terms of clearance(s) and
volume(s) using the subroutine ADVAN6 TRANS1 TOL5 in
NONMEM. The analyses were performed using different estima-
tion methods (first-order, FO; first-order conditional estimation,
FOCE, with or without interaction). For the final model, FOCE with
interaction was used.
Covariate model building
To advance the population analysis, a covariate analysis was
performed starting from the base model. The analysis included two
sequential methods to investigate whether covariates could explain
part of the variability of the PK parameters: the GAM analysis
Table 1 Study characteristics with matuzumab given as multiple 1h i.v. infusions ranging from 400 to 2000mg, q1w–q3w
Study Tumour entity Dose regimen Planned sampling times
a
No. of
subjects
1 Advanced pancreatic
cancer
400mg q1w; 800mg q2w; 800mg q1w Baseline, 1, 2, 5, 48, 96, 168, 672, 673, 674, 677, 720, 840
b 17
2 Various advanced cancer
(mainly colon/rectum
cancer)
1200mg q1w, q2w, q3w; 400mg q3w; 800mg
q3w; 1600mg q3w
For q1w: baseline, 1, 2, 5, 48, 96, 168
b; for q2w: baseline, 1,
2, 5, 48, 96, 168, 336
b; for q3w: baseline, 1, 2, 5, 48, 168,
336, 504, 505, 506, 509, 552, 672, 840, 1008
b
51
3 Various advanced cancer
(mainly colon/rectum
cancer)
400mg q1w; 800mg q1w; 1200mg q1w;
1600mg q1w; 2000mg q1w (from week2:
1600mg)
Baseline, 1, 2, 5, 24, 72, 96, 168, 504, 505, 506, 509, 528,
576, 600, 672
b
22
aRelative time elapsed after start of first infusion, in hours.
bBefore and after several other infusions peak and trough concentrations were analysed.
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s(‘generalised additive modelling’, implemented in the software
Xpose
s), using the Akaike’s Information Criterion (Jonsson and
Karlsson, 1999; Pan, 2001), and the covariate analysis within
NONMEM. The GAM analysis allowed a fast initial screening of
covariates (Mandema et al, 1992), which were retrieved by the
insertion of covariate relations into the NONMEM model. In
NONMEM, all covariate relations were investigated by forward
inclusion and backward deletion techniques. The final covariate
model was built in a stepwise manner. In each step, all possible/
remaining parameter–covariate relations were assessed. The
included covariate relation that led to the largest drop in the
objective function value (OFV), the criterion for model evaluation,
was kept in the model. In the next steps, the remaining covariate
relations were investigated. All covariate relations that caused a
DOFV4 3.84 (Po0.05, df¼1) formed the full covariate model.
From the full model, the covariate relations were then deleted one
at a time using a stricter criterion (DOFV410.83, Po0.001,
df¼1). The final covariate model was achieved when deletion of
each covariate relation was significant.
Covariates investigated for their influence on PK parameters
included continuous characteristics as demographics (weight
(WT), height (HT), age, body surface area (BSA), body mass
index (BMI)), laboratory values (creatinine clearance (CLCR),
lactate dehydrogenase (LDH), alkaline phosphatase (AP), white
blood cell count (WBC)) and others (Karnofsky index, dose
group (DSG)), as well as the categorical characteristics (sex,
study number, study site (SID) and concomitant chemotherapy
(COME)).
Continuous covariates were investigated with a linear covariate
model:
TVPk ¼ yk  ð 1 þ yCOV  ð COV   COVmedianÞÞ
where TVPk is the population value of the parameter Pk for a
specific covariate value (COV) and yk is the population value of the
parameter Pk with the covariate value being the median value
(COVmedian). ycov is the fractional change in the population
parameter with each unit change from the median covariate value.
Whether graphical inspection suggested, nonlinear relations were
investigated with a power model, an Emax model or an exponential
model.
Categorical covariates were given as dichotomous variables (sex:
male/female, concomitant chemotherapy: yes/no). The coding will
be illustrated using an indicator variable (IND), being 0 or 1 (e.g.
male or female).
TVPk ¼ yk  ð 1 þ yCOV  ð INDÞÞ
where yk is the typical value of the parameter Pk when IND¼0.
ycov represents the fractional increase or decrease of the parameter
Pk caused by IND¼1.
If the categorical covariate had multiple categories, each
category had an IND (e.g. study site: site 1¼(IND) 1, etc.).
TVPk1 ¼ yk1 if ðINDÞ¼1; etc
where ykx is the typical value of the parameter Pk for each
categoryx.
Visual exploratory analysis of the covariate relations revealed
that for the laboratory parameters aspartate aminotransferase,
alanine aminotransferase, gamma glutamyltransferase and bilir-
ubin, a ‘relation’ was driven by very few individuals. Neglecting
these individuals did not support the relation anymore. Conse-
quently, these relations were not considered in further covariate
analysis.
RESULTS
Patient population
Patient characteristics with descriptive statistics are presented in
Table 2. For all parameters, the range was wide, for example, age
was varying from 29 to 82 years, which was beneficial for the
ability to identify covariate relations. The table also includes the
number of the missing values that were replaced for the model-
building process by the respective median value.
Base model
A total of 1256 serum concentrations from 0.258 to 1157mgml
 1
were simultaneously analysed. The average number of concentra-
tions per patient was 15 (range: 5–24). Serum concentration–time
profiles were best described by a two-compartment model (e.g.
DOFV4 300 compared with a one-compartment model,
Po0.05). Within this model in addition to the linear clearance
(CLL), a second elimination pathway as a nonlinear process
(Michaelis–Menten kinetics, CLNL) from the central compartment
was included with the additional parameters Vmax, the maximum
elimination rate (mgh
 1), and Km, the concentration (mgml
 1)
with half-maximal elimination rate (DOFV4 100). A need to
incorporate nonlinearity might also be concluded from the
semilogarithmic plots in Figure 1, showing the geometric mean
and the standard deviation of the observed concentration–time
profiles of four weekly dose regimens of 400–1600mg, after the
first and fourth infusion. In the terminal phase, the slope of the
curve was steeper at lower concentrations.
The final base structural model is shown in Figure 2. In
this model, the input was the route of administration
(i.v. infusion). The central compartment with the central
volume of distribution (V1) was linked with the peripheral
compartment with the peripheral volume of distribution (V2) via
Table 2 Characteristics of the study population (ID¼subject) including number or median, range and number of missings
Study 1 Study 2 Study 3 Total Missings
Number of IDs, (male/female) 17 (9/8) 51 (33/18) 22 (11/11) 90 (53/37) 0
Age (years), median (min–max.) 65 (40–82) 57 (29–78) 58 (30–71) 60 (29–82) 0
Height (cm), median (min–max) 168 (156–183) 169 (143–198) 170 (150–184) 169 (143–198) 3
Weight (kg), median (min–max) 68 (48–81) 71 (47–125) 72 (44–98) 71 (44–125) 3
Body mass index (kgm
 2), median (min–max) 24.7 (17.0–30.7) 25.8 (20.1–37.0) 24.3 (15.9–33.9) 24.9 (15.9–37.0) 4
Body surface area (m
2), median (min–max) 1.77 (1.51–2.01) 1.82 (1.34–2.59) 1.85 (1.44–2.16) 1.82 (1.34–2.59) 4
Creatinine clearance (mlmin
 1), median (min–max) 104 (71–480
a) 83 (47–180) 108 (47–226) 91 (41–480
a)3
Alkaline phosphatase (Ul
 1), median (min–max) 190 (118–1026) 156 (40–403) 235 (96–1309) 171 (40–1309) 0
Lactate dehydrogenase (Ul
 1), median (min–max) 171 (117–926) 542 (305–8041) 187 (76–3243) 426 (76–8041) 0
Study centre number (number of IDs) 1 2
(8) (9)
3
(51)
4
(22)
123 4
(8) (9) (51) (22)
0
Combination chemotherapy, number of IDs 17 0 0 17 0
aSpurious value in original data set, but without influence on population pharmacokinetic analysis.
Population pharmacokinetics of matuzumab
K Kuester et al
902
British Journal of Cancer (2008) 98(5), 900–906 & 2008 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sQ, the intercompartmental clearance. Implementation of CLNL
from the peripheral compartment only or from both compart-
ments did not result in an improvement of the model. The linear
part of clearance was estimated to be 14.6mlh
 1 and the nonlinear
part, calculated from the parameters Km (5.3mgl
 1) and Vmax
(0.552mgh
 1) at mAb concentrations 5Km, to be 104.2mlh
 1,
respectively.
Total clearance as the sum of CLL and CLNL was 118.8mlh
 1
(at mAb concentrations 5Km). In Figure 3 left panel, the
dependence of total clearance on the concentration of the mAb
is presented. At low mAb concentrations, until approximately
1mgml
 1, total clearance (solid line) was mainly influenced by the
nonlinear clearance part (long-dashed line). At higher mAb
concentrations, the impact of the nonlinear part on the total
clearance decreased and the linear part (short-dashed line) was
dominating. In accordance with the nonlinear behaviour, the half-
life ranged between 4.4 and 10.5 days at concentrations of 20 and
1000mgml
 1, respectively (Figure 3, right panel).
Interindividual variability was quantified for CLL, V1, V2
and Vmax, and in addition, IOV was implemented. The inclusion
of IOV was limited to eight infusions due to insufficient data
hereafter and implemented by different ways of assigning the eight
infusions to a varying number of occasions. The best result (lowest
OFV, smallest relative standard errors in % (RSE¼standard error
divided by population estimate*100)) was achieved with IOV on
CLL, where every infusion corresponded to one occasion
(DOFVB 400).
In general, in the base model, IIV was moderate (24–60% CV)
and larger than IOV of 23% CV. Residual variability was best
implemented with a combined error model with a proportional
error of 13% CV and an additive error of 0.312mgl
 1, being fixed
due to model stability (the value was chosen from prior plausible
successfully run models).
The parameters obtained from the base model are shown in
Table 3, left part, including the RSE. All parameters were generally
estimated with good precision (RSEp37.1%, except for IIV on CLL
and Vmax p49.4%).
Final model
Fourteen covariate relations were found by GAM: VmaxBBSA, sex,
CLCR; V1BBSA, COME, sex; V2BCOME, sex, LDH, SID;
CLLBBSA, COME, AP, sex.
These screening results were included into the NONMEM base
model. After forward inclusion, the full covariate model contained
eight relations: VmaxBBSA; V1BWT, DSG, COME; V2BBSA, DSG,
COME; CLLBBSA (DOFV in total:  102). After backward
elimination, the remaining statistically significant covariate rela-
tions were V1BWT, DSG, V2BCOME and CLLBBSA. The OFV
compared with the base model was reduced by 69.
The significant relations identified by NONMEM were further
examined for plausibility and relevance. Body size measures were
identified to be plausible explanatory factors for the PK parameters
V1 and CLL. Regarding the influence of DSG on V1, the graphical
inspection indicated that the relation was driven by very few
patients only in the highest dose group. In addition, the influence
of the dose group was inspected by simulation of ‘dummy’ patients
of the lowest-, median- and highest-dose group. As the resulting
concentration–time profiles were very similar, this covariate
relation was removed from the model. An analogous procedure
was performed for the covariate COME on CLL. No major
difference was found, and, as additionally, no biologically plausible
explanation can be given for this covariate relation, it was also
removed from the model.
During covariate modelling, IIV on Vmax decreased from the
base to the final covariate model, although no covariate on Vmax
was included. Therefore, different correlations were investigated
revealing correlations between Vmax, V1 and V2. The correlation
coefficients are given in Table 3 (right panel). After the inclusion of
the correlations, the model contained the remaining covariates WT
on V1 and BSA on CLL. As BSA and WT were highly correlated, it
was examined whether the covariate BSA could be exchanged by
WT. It was shown that the model with WT on CLL was not inferior
to the model with BSA on CLL. From the individual plots
(observed and predicted concentrations vs time), no difference
between the two covariate models was seen. Additionally,
compared with WT, BSA displayed a relatively small range of
values, and especially there were only few study patients with high
BSA values. Another criterion to support the replacement of the
covariates was given by the inspection of the distribution of the
individual CLL. The model with WT on CLL better followed a
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Figure 1 Semilogarithmic plot of the geometric mean and the standard deviation of the observed concentration–time profiles of the four weekly dose
regimens (400, 800, 1200 and 1600mg per week) after the first (left panel) and fourth (right panel) infusion. n¼number of patients in the dose group. Last
time point for 1600mg dose group was after 1008h and is not shown.
Q
R0=D/T
Infusion
Central
compartment 
(V1)
Peripheral
compartment 
(V2)
CLL Vmax
Km
Figure 2 Schematic structural pharmacokinetic model. R0¼infusion
rate; D¼dose; T¼infusion duration; V1¼volume in the central compart-
ment; Q¼intercompartmental clearance; V2¼volume in the peripheral
compartment; CLL¼linear clearance part; Vmax¼maximum elimination
rate; Km¼concentration at which the elimination rate is 50% of the
maximum value.
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snormal distribution pattern. The exchange of the covariates caused
an increase in the OFV by only 3.4. As WT is a directly measured
variable in the daily clinical process compared with the derived
variable BSA, and because, in summary, it was demonstrated that
similar results were obtained from the covariate exchange, the final
model included WT on CLL instead of BSA, besides WT on V1.A
deviation of  19% to þ25% of the population PK parameters (V1,
CLL) for the 5th and 95th percentile of the WT values in the study
population with respect to the population PK parameters for the
median WT value was observed.
All parameter estimates obtained from the final model are
shown in Table 3 (right part). V1, V2, CLL, Q, Vmax and Km of the
final model were similar to the estimates of the base model. IIV on
CLL and V1 decreased by 25 and 10%, respectively. In general, all
parameters were estimated with a better precision than in the base
model (RSEo39%). Especially for the IIV (except on V1) and IOV,
more precise estimates were obtained.
In Figure 4, the goodness-of-fit plots obtained from the final
population PK model in linear (left) and logarithmic (right) scale
are shown. The upper panel presents the population predictions vs
the observed concentrations. Especially the data points in the low
region were uniformly spread around the line of unity with a slight
underprediction in the higher region. Examining the lower panel
with individual predicted vs observed concentrations, those in the
higher region were more uniformly scattered, and the lower
concentrations were closer to the line of unity. Overall, the plots
indicate that the study data were sufficiently well described by the
developed model.
DISCUSSION AND CONCLUSION
In this study, a population PK analysis was performed for the
humanised mAb matuzumab directed against the EGFR with data
Table 3 Population pharmacokinetic estimates of matuzumab obtained from the base and the final model
Base model Final model
Model parameter Unit Population estimate RSE
a, % Population estimate RSE
a,%
Fixed effects
CLL
b mlh
 1 14.6 7.1 14.5 4.1
V1 l 3.73 2.5 3.72 3.0
Q mlh
 1 36.2 17.7 38.3 7.6
V2 l 1.8 8.6 1.84 9.0
Vmax mgh
 1 0.552 17.7 0.456 13.7
Km mgl 1 5.3 27.0 4.0 29.8
Covariate influence
V1_WT
b,c — — 0.0044 35.2
CLL_WT
b,d — — 0.0087 28.2
Random effects
Interindividual variability
o CLL
b %CV 31.9 42.7 24.0 20.5
o V1 %CV 24.4 17.9 21.9 20.3
o V2 %CV 59.8 33.3 61.6 27.6
o Vmax %CV 48.3 49.4 53.8 38.1
Correlation V1_V2 — — 0.777 29.8
Correlation V2_Vmax — — 0.875 31.6
Correlation V1_Vmax — — 0.875 28.4
Interoccasion variability
p CLL
b %CV 22.6 37.1 22.8 12.6
Residual error
s proportional %CV 13.3 5.8 13.4 1.5
s additive mgl
 1 0.312 (fixed) — 0.312 (fixed) —
aRelative standard error (standard error divided by population estimate*100; for the random effects parameters RSE is related to the corresponding variance scale).
bCLL: linear
clearance part; CLNL: nonlinear clearance part (at concentrations5Km); WT: weight.
cV1,individual¼V1*[1+V1_WT*(WT WTmedian)]*EXP(ZV1).
dCLLindividual¼CLL*[1+CLL_WT*(WT WTmedian)]*EXP(ZCLL+kCLL).
g CLNL
b¼104.2mlh 1 g CLNL
b¼114.0mlh 1
g Correlation coefficients
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Figure 3 Left panel: dependence of clearance on concentration (C) of the mAb. Right panel: dependence of half-life (in days) on C.
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sfrom three phase I studies. The model was developed using over
1200 serum concentration data points from 90 cancer patients with
widely differing characteristics and multiple dosing regimens.
The structural model comprised two compartments with two
elimination pathways from the central compartment, one linear
and one nonlinear (Michaelis–Menten). Nonlinear PK behaviour
has also been reported for other mAbs, such as sibrotuzumab and
clenoliximab (Mould et al, 1999; Kloft et al, 2004). It has also been
investigated in addition to the linear elimination for rituximab,
but the model did not perform significantly better than the
simple linear model. However, goodness-of-fit plots suggest a
misspecification for high concentrations (Ng et al, 2005).
With respect to the structural model, matuzumab was initially
distributed to a restricetd central volume of distribution of
3.7l and an even smaller peripheral volume of distribution
of 1.8l, which indicated that matuzumab was not (largely)
distributed apart from serum volume. Beside the low peripheral
volume, the intercompartmental clearance Q also indicated
a limited distribution, which was consistent with the behaviour
of endogenous IgG immunoglobulins (Morell et al, 1970;
Koleba and Ensom, 2006; Kuester and Kloft, 2006). In total,
matuzumab showed similar PK characteristics (clearance and
volumes of distribution) to other therapeutic mAbs following
intravenous administration (Mould et al, 1999; Kovarik et al, 2001;
Bruno et al, 2005).
Three components of random variability (interindividual,
interoccasional and residual) were implemented into the matuzu-
mab model. With the relatively small residual variability (13.4%
CV for the proportional part and a fixed additive error of
0.312mgl
 1), it can be suggested that the developed model possess
reasonably high predictability. IOV has been rarely investigated in
mAb research, but in more recent population PK analysis, it has
been included to improve the model (Kloft et al, 2004; Fang et al,
2007). The estimated IOV of matuzumab (23% CV; RSE, 13%) was
in the range or slightly higher than that for other immunologicals:
sibrotuzumab, humanised antibody HuCC49CH2 and etanercept
showed 13, 11 and 28% CV, as well as RSE imprecisions of 25 and
102% (not reported for etanercept), respectively (Lee et al, 2003;
Kloft et al, 2004; Fang et al, 2007). The importance of
implementing IOV in population PK analysis has been demon-
strated (Karlsson and Sheiner, 1993) and investigation of IOV
avoids biased population parameter estimates.
The aim of building the covariate model was to find patient- or
study-specific characteristics, which could explain and thus reduce
the variability of the base model. The inclusion of the covariates
WT on V1 and WT on CLL showed a significant improvement of
the model, which could be seen by the reduction of the IIV on CLL
by approximately 25%. As no difference was observed between
patients of either sex and between matuzumab as a single agent
and in combination with gemcitabine, no effect of sex and
gemcitabine on the PK of matuzumab might be assumed.
Additionally, kidney and liver functions do not seem to influence
the PK. These results are in good agreement with investigations of
other mAbs. The population PK analysis for trastuzumab showed a
significant influence of WT on V1 but was not considered clinically
relevant (Bruno et al, 2005). Similar results have been reported for
the chimeric antibody basiliximab (Kovarik et al, 2001). The
incorporation of WT on V1 for golimumab, a fully human mAb,
significantly improved the model (Zhou et al, 2007).
Future research could attempt to explain the mechanism of
nonlinearity in the PK. An appealing approach might present
physiologically based modelling including processes, such as
receptor internalisation. It has been demonstrated that binding
of a mAb to the neonatal Fc receptor (FcRn) and internalisation of
the resulting complex results in the long serum half-life of the
antibody (Brambell et al, 1964; Ghetie et al, 1997). Comparing a
modified therapeutic antibody (different Fc part) with its original
antibody, the resulting half-life for the modified antibody was
shorter. It could be assumed that the modified antibody might less
be able to bind to the FcRn and thus, was less protected from
elimination (Fang et al, 2007).
The overall aim of this final model could be, when correlated to
PD or efficacy data, to serve as a tool to guide selection of optimal
dose regimens for matuzumab, a highly promising ‘targeted’
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Figure 4 Goodness-of-fit plots. Population predictions (upper panel) and individual predictions (lower panel) vs observed matuzumab serum
concentrations are shown using linear (left) and logarithmic (right) scale of both axes.
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scancer therapy. From the performed covariate analysis, it should
already be recognised that the results do not suggest dose
adjustments for sex, age or organ functions such as liver or
kidney. For future studies, the identification of molecular tumour
markers are considered as being essential prerequisites to be
linked to the PK results in a pharmacokinetic/pharmacodynamic
model. This could lead to a better prediction of the response for
this new class agent and maximise the patient’s benefit.
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